

Quanex Building Products Announces Fourth Quarter and Fiscal Year 2017 Results

Over \$45 Million of Bank Debt Paid Down in 2017 Growth and Margin Expansion Expected in 2018

HOUSTON, TEXAS – December 11, 2017 - **Quanex Building Products Corporation** (NYSE:NX) ("Quanex" or the "Company") today announced its results for the quarter and fiscal year ended October 31, 2017.

Bill Griffiths, Chairman, President and Chief Executive Officer, commented, "Fiscal 2017 was a year with a lot of moving parts related to eliminating low margin business from the portfolio, consolidating facilities and redeploying assets; however, we are now well positioned for growth and margin expansion in 2018. The hurricanes that hit Texas and Florida in August and September created some softness and inefficiencies during the fourth quarter, mostly in our North American Cabinet Components segment, but we anticipate incremental demand for our products in the coming months and years as rebuilding efforts continue. Looking past the noise, the underlying growth rate for our legacy fenestration business in the U.S. was 6.1% in fiscal 2017, which is more than double Ducker's latest window shipment estimate of 2.9% growth for the twelve months ended September 30, 2017. Free cash flow continued to be strong in fiscal 2017, which allowed us to repay more than \$45 million of bank debt. Looking ahead, we will continue to focus on generating cash and deleveraging the balance sheet."

Fourth Quarter and Fiscal Year 2017 Results Summary

| | Three Months Er | ded October 31, | Twelve Months Ended October | | | | | |
|----------------------|-----------------|-----------------|-----------------------------|----------|--|--|--|--|
| | 2017 | 2016 | 2017 | 2016 | | | | |
| Net Sales | \$233.0 | \$249.2 | \$866.6 | \$928.2 | | | | |
| Net Income (loss) | \$10.7 | \$5.4 | \$18.7 | (\$1.9) | | | | |
| Diluted EPS | \$0.31 | \$0.16 | \$0.54 | (\$0.05) | | | | |
| Adjusted Net Income | \$13.1 | \$15.7 | \$27.0 | \$27.7 | | | | |
| Adjusted Diluted EPS | \$0.37 | \$0.45 | \$0.77 | \$0.82 | | | | |
| Adjusted EBITDA | \$33.3 | \$34.6 | \$99.0 | \$110.3 | | | | |

Quanex reported the following selected financial results:

(See Non-GAAP Terminology Definitions and Disclaimers section, Non-GAAP Financial Measure Disclosure table and Selected Segment Data table for additional information)

The decreases in net sales were largely driven by the Company's decision to exit business that does not meet its financial objectives. (See Sales Analysis table for additional information)

The decreases in adjusted earnings were primarily attributable to lower volumes and short-term inefficiencies related to transitioning away from less profitable business throughout the year coupled with the impact of hurricanes in the U.S. during the fourth quarter. (See Non-GAAP Terminology Definitions and Disclaimers section, Non-GAAP Financial Measure Disclosure table and Selected Segment Data table for additional information)

As of October 31, 2017, Quanex's leverage ratio of Net Debt to LTM Adjusted EBITDA was 2.3x. The Company remains focused on generating Free Cash Flow to pay down debt and expects to end fiscal 2018 with a leverage ratio below 2.0x. (See Non-GAAP Terminology Definitions and Disclaimers section for additional information)

Business Update

Quanex divested its non-core wood flooring business, Owens Flooring, on October 31, 2017. Owens Flooring contributed \$9.4 million of revenue and net income of less than \$0.1 million, excluding the loss on the sale of the plant, in fiscal 2017.

Outlook

Bill Griffiths, Chairman, President and Chief Executive Officer, stated, "We continue to be encouraged by the macro indicators that impact our business and believe this housing cycle has several years to run at low-to-mid single-digit growth rates for Quanex as a whole. In fact, after adjusting for the foreign exchange impact, the divestiture of the wood flooring business and other business we consciously shed, the consolidated business grew at 4.4% in 2017. We anticipate a similar growth rate in 2018. As a result, we expect to generate net sales of \$890 million to \$900 million and Adjusted EBITDA* of \$103 million to \$108 million."

*When Quanex provides expectations for Adjusted EBITDA on a forward-looking basis, a reconciliation of the differences between the non-GAAP expectations and corresponding GAAP measures is generally not available without unreasonable effort. Certain items required for such a reconciliation are outside of the Company's control and/or cannot be reasonably predicted or estimated, such as the provision for income taxes.

Conference Call and Webcast Information

The Company has scheduled a conference call for Tuesday, December 12, 2017, at 11:00 a.m. ET (10:00 a.m. CT). To participate in the conference call dial (877) 388-2139 for domestic callers and (541) 797-2983 for international callers, in both cases using the conference passcode 5996538, and ask for the Quanex call a few minutes prior to the start time. A link to the live audio webcast will also be available on the Company's website at <u>http://www.quanex.com</u> in the Investors section under Presentations & Events. A telephonic replay of the call will be available approximately two hours after the live broadcast ends and will be accessible through December 19, 2017. To access the replay dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers, in both cases referencing conference passcode 5996538.

About Quanex

Quanex Building Products Corporation is an industry-leading manufacturer of components sold to Original Equipment Manufacturers (OEMs) in the building products industry. Quanex designs and produces energy-efficient fenestration products in addition to kitchen and bath cabinet components.

For more information contact Scott Zuehlke, Vice President, Investor Relations & Treasurer, at 713-877-5327 or <u>scott.zuehlke@quanex.com</u>.

Non-GAAP Terminology Definitions and Disclaimers

Adjusted Net Income (Loss) (defined as net income further adjusted to exclude purchase price accounting inventory step-ups, transaction costs, gain/loss on the sale of fixed assets, one-time employee benefit adjustment, restructuring charges, adjustments related to accelerated depreciation and amortization for restructured PP&E and intangible assets, interest expense adjustments related to the write off of deferred loan costs, unamortized original issuance discount and prepayment call premium related to debt refinance, other net adjustments related to foreign currency transaction gain/loss and effective tax rates reflecting impacts of adjustments on a with and without basis) and Adjusted EPS are non-GAAP financial measures that Quanex believes provide a consistent basis for comparison between periods and more accurately reflects operational performance, as they are not influenced by certain income or expense items not affecting ongoing operations, EBITDA (defined as net income or loss before interest, taxes, depreciation and amortization and other, net) and Adjusted EBITDA (defined as EBITDA further adjusted to exclude purchase price accounting inventory step-ups, transaction costs, gain/loss on the sale of fixed assets, one-time employee benefit adjustment and restructuring charges) are non-GAAP financial measures that the Company uses to measure operational performance and assist with financial decisionmaking. Net Debt is calculated using the sum of current maturities of long-term debt and long-term debt, minus cash and cash equivalents. The leverage ratio of Net Debt to LTM Adjusted EBITDA is a financial measure that Quanex believes is useful to investors and financial analysts in evaluating the Company's leverage. In addition, with certain limited adjustments, this leverage ratio is the basis for a key covenant in Quanex's credit agreement. Free Cash Flow is a non-GAAP measure calculated using cash provided by operating activities less capital expenditures. Quanex believes that the presented non-GAAP measures provide a consistent basis for comparison between periods, and will assist investors in understanding the Company's financial performance when comparing results to other investment opportunities. The presented non-GAAP measures may not be the same as those used by other companies. Quanex does not intend for this information to be considered in isolation or as a substitute for other measures prepared in accordance with U.S. GAAP.

Forward Looking Statements

Statements that use the words "estimated," "expect," "could," "should," "believe," "will," "might," or similar words reflecting future expectations or beliefs are forward-looking statements. The forward-looking statements include, but are not limited to, the Company's future operating results, future financial condition, future uses of cash and other expenditures, expenses and tax rates, expectations relating to Quanex's industry, and the Company's future growth, including any guidance discussed in this press release. The statements and guidance set forth in this release are based on current expectations. Actual results or events may differ materially from this release. For a complete discussion of factors that may affect Quanex's future performance, please refer to the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 2016, under the sections entitled "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors". Any forward-looking statements in this press release are made as of the date hereof, and Quanex undertakes no obligation to update or revise any forward-looking statements to reflect new information or events.

QUANEX BUILDING PRODUCTS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(In thousands, except per share data) (Unaudited)

| | Three Months Ended October 31, | | | | | Twelve Months Ended October 31 | | | | | | | |
|---|--------------------------------|---------|----|---------|----|--------------------------------|----|----------|--|--|--|--|--|
| | | 2017 | | 2016 | | 2017 | | 2016 | | | | | |
| Net sales | \$ | 232,959 | \$ | 249,171 | \$ | 866,555 | \$ | 928,184 | | | | | |
| Cost of sales | | 178,325 | | 188,168 | | 672,162 | | 710,644 | | | | | |
| Selling, general and administrative | | 23,142 | | 26,480 | | 97,981 | | 114,910 | | | | | |
| Restructuring charges | | 1,467 | | 529 | | 4,550 | | 529 | | | | | |
| Depreciation and amortization | | 13,794 | | 13,387 | | 57,495 | | 53,146 | | | | | |
| Asset impairment charges | | - | | 12,602 | | - | | 12,602 | | | | | |
| Operating income | | 16,231 | | 8,005 | | 34,367 | | 36,353 | | | | | |
| Interest expense | | (2,469) | | (2,174) | | (9,595) | | (36,498) | | | | | |
| Other, net | | 158 | | (1,443) | | 730 | | (5,479) | | | | | |
| Income (loss) before income taxes | | 13,920 | | 4,388 | | 25,502 | | (5,624) | | | | | |
| Income tax (expense) benefit | | (3,188) | | 1,043 | | (6,819) | | 3,765 | | | | | |
| Net income (loss) | \$ | 10,732 | \$ | 5,431 | \$ | 18,683 | \$ | (1,859) | | | | | |
| Income (loss) per common share, basic | \$ | 0.31 | \$ | 0.16 | \$ | 0.55 | \$ | (0.05) | | | | | |
| Income (loss) per common share, diluted | \$ | 0.31 | \$ | 0.16 | \$ | 0.54 | \$ | (0.05) | | | | | |
| Weighted average common shares outstanding: | | | | | | | | | | | | | |
| Basic | | 34,493 | | 33,953 | | 34,230 | | 33,876 | | | | | |
| Diluted | | 35,169 | | 34,536 | | 34,837 | | 33,876 | | | | | |
| Cash dividends per share | \$ | 0.04 | \$ | 0.04 | \$ | 0.16 | \$ | 0.16 | | | | | |

QUANEX BUILDING PRODUCTS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands) (Unaudited)

| | Octob | er 31, 2017 | Octob | er 31, 2016 |
|--|-------|-------------|-------|-------------|
| ASSETS | | | | |
| Current assets: | | | | |
| Cash and cash equivalents | \$ | 17,455 | \$ | 25,526 |
| Accounts receivable, net | | 79,411 | | 83,625 |
| Inventories, net | | 87,529 | | 84,335 |
| Prepaid and other current assets | | 7,406 | | 10,488 |
| Total current assets | | 191,801 | | 203,974 |
| Property, plant and equipment, net | | 211,131 | | 198,497 |
| Goodwill | | 222,194 | | 217,035 |
| Intangible assets, net | | 139,778 | | 154,180 |
| Other assets | | 8,975 | | 6,667 |
| Total assets | \$ | 773,879 | \$ | 780,353 |
| LIA BILITIES AND STOCKHOLDERS' EQUITY | | | | |
| Current liabilities: | | | | |
| Accounts payable | \$ | 44,150 | \$ | 47,781 |
| Accrued liabilities | | 38,871 | | 55,101 |
| Income taxes payable | | 2,192 | | 732 |
| Current maturities of long-term debt | | 21,242 | | 10,520 |
| Total current liabilities | | 106,455 | | 114,134 |
| Long-term debt | | 218,184 | | 259,011 |
| Deferred pension and postretirement benefits | | 4,433 | | 8,167 |
| Deferred income taxes | | 21,960 | | 18,322 |
| Other liabilities | | 16,000 | | 12,888 |
| Total liabilities | | 367,032 | | 412,522 |
| Stockholders' equity: | | | | |
| Common stock | | 375 | | 376 |
| Additional paid-in-capital | | 255,719 | | 254,540 |
| Retained earnings | | 225,704 | | 214,047 |
| Accumulated other comprehensive loss | | (25,076) | | (38,765) |
| Treasury stock at cost | | (49,875) | | (62,367) |
| Total stockholders' equity | | 406,847 | | 367,831 |
| Total liabilities and stockholders' equity | \$ | 773,879 | \$ | 780,353 |

QUANEX BUILDING PRODUCTS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(In thousands) (Unaudited)

| Z017 Z016 Operating activities: s 18,683 \$ (1,859) Adjustments to reconcile net income (loss)' to cash provided by operating activities: 57,495 53,146 Depreciation and amortization 57,495 53,146 Stock-based compensation (248) (112) (8,469) Excess tax benefit from share-based compensation (248) (200) Charge for deferred loan costs and debt discount - 16,022 Asset impairment charge - - 12,602 Gain on involuntary conversion - | | Twe | lve Months E | nded O | ctober 31, |
|--|--|-----|--------------|--------|------------|
| Net income (loss) \$ 18,683 \$ (1,859) Adjustments to reconcile net income (loss)' to cash provided by operating activities: 57,495 53,146 Depreciation and amortization 5,189 6,089 Deterred income tax (112) (8,469) Excess tax benefit from share-based compensation (248) (136) Loss (gain) on the disposition of capital assets 1,528 (20) Charge for deferred loan costs and debt discount - 12,602 Gain on involuntary conversion - - 2,602 Gain on involuntary conversion - - - 2,602 Charges in assets and liabilities, net of effects from acquisitions: - - - - Decrease in accounts payable (4,893) (2,273) - - - Charges in other current assets 1,86 2,503 - - - Decrease in accounts payable (4,493) (2,273) - - - Increase in other long-term liabilities 1,86 2,307 - - < | | | 2017 | | 2016 |
| Adjustments to reconcile net income (loss)' to cash provided by operating activities:Depreciation and amortization $57,495$ Stock-based compensation $5,189$ 6,089Deferred income tax(112)Excess tax benefit from share-based compensation(248)Loss (gain) on the disposition of capital assets $1,528$ (20)Charge for deferred loan costs and debt discount-16,022Asset impairment charge-Cain on involuntary conversionOther, net $1,741$ 339Changes in assets and liabilities, net of effects from acquisitions:Decrease in accounts receivable $5,378$ Optercase in other current assets1862,503Decrease in inventory(3,240) $5,346$ Increase in accured liabilities(8,497)1,246Increase (decrease) in income taxes4,670(365)(Decrease) increase in accured inabilities1,382956Other, net(1)588Increase (decrease) in income taxes4,670(3,554)(3,564)Increase in other long-term liabilities1,382956Other, netCash provided by operating activities1,382956Other, netCash provided by operating activities10Cash acquired(3,564)(3,273)(1,245)(245,904)Captal expenditures(3,46,412)10Cash used forn insposition of capital assets1,3371,0 | Operating activities: | | | | |
| Depreciation and amortization $57,495$ $53,146$ Stock-based compensation $5,189$ $6,089$ Deferred income tax (112) $(8,469)$ Excess tax benefit from share-based compensation (248) (136) Loss (gain) on the disposition of capital assets $1,528$ (20) Charge for deferred loan costs and debt discount- $15,022$ Asset impairment charge- $12,602$ Gain on involuntary conversionOther, net $1,741$ 339 Changes in assets and liabilities, net of effects from acquisitions:-Decrease in accounts receivable $5,3,78$ 796(Increase) decrease in inventory $(3,240)$ $5,346$ Increase in other current assets 186 $2,503$ Decrease in accounts payable $(4,893)$ $(2,273)$ Decrease in other current assets $4,670$ (365) (Decrease) increase in accrued liabilities $1,82$ 956Other, net (2437) (93) Cash provided by operating activities $4,670$ (365) Inversting activities: $(41,124)$ $(282,103)$ Financing activities: $(41,124)$ $(282,103)$ Financing activities: $(41,124)$ $(282,103)$ Financing activities: $(5,516)$ $(5,470)$ Stasen costs $ (11,435)$ Repayments of credit facility borrowings $(98,875)$ $(422,875)$ Det tissuance costs $ (11,435)$ Repayments of credit facility borrowings | Net income (loss) | \$ | 18,683 | \$ | (1,859) |
| Stock-based compensation 5,189 6,089 Deferred income tax (112) (8,469) Excess tax benefit from share-based compensation (248) (136) Loss (gain) on the disposition of capital assets 1,528 (20) Charge for deferred loan costs and debt discount - 16,022 Asset impairment charge - 12,602 Gain on involuntary conversion - - Other, net 1,741 339 Changes in assets and liabilities, net of effects from acquisitions: Decrease in accounts receivable 5,378 796 Chorease) decrease in inventory (3,240) 5,346 Increase in other current assets 186 2,503 Decrease in accounts payable (4,893) (2,273) (Decrease) increase in decrued pension and postretirement benefits (271) 588 Increase (decrease) in neome taxes 4,670 (365) (0ther, net (437) (93) Cash provided by operating activities 78,554 86,418 Investing activities 1,937 1,044 Increase in other long-term liabilities (34,564) | Adjustments to reconcile net income (loss)' to cash provided by operating activities | : | | | |
| Deferred income tax (112) (8,469) Excess tax benefit from share-based compensation (248) (136) Loss (gain) on the disposition of capital assets 1,528 (20) Charge for deferred loan costs and debt discount - 16,022 Asset impairment charge - 12,602 Gain on involuntary conversion - - Other, net 1,741 339 Changes in assets and liabilities, net of effects from acquisitions: - - Decrease in accounts receivable 5,378 796 (Increase) decrease in inventory (3,240) 5,344 Increase in other current assets 186 2,503 Decrease in accounts payable (4,893) (2,273) (Decrease) increase in deferred pension and postretirement benefits (271) 588 Increase (decrease) in income taxes 4,670 (365) Other, net (437) (93) Cash provided by operating activities 78,554 86,418 Increase in other long-term liabilities 1,937 1,044 Cash used for investing activ | Depreciation and amortization | | 57,495 | | 53,146 |
| Excess tax benefit from share-based compensation (248) (136) Loss (gain) on the disposition of capital assets 1,528 (20) Charge for deferred loan costs and debt discount - 16,022 Asset impairment charge - 12,602 Gain on involuntary conversion - - Other, net 1,741 339 Changes in assets and liabilities, net of effects from acquisitions: - - Decrease in accounts receivable 5,378 796 (Increase) decrease in inventory (3,240) 5,343 Decrease in other current assets 186 2,503 Decrease in other current assets 186 2,503 Decrease in increase in accounts payable (4,893) (2,273) (Decrease) increase in accrued liabilities 1,382 956 Increase in other long-term liabilities 1,382 956 Other, net (437) (93) Cash provided by operating activities 78,554 86,418 Investing activities: (41,124) (245,04) Acquisitions, net of cash acquired | Stock-based compensation | | 5,189 | | 6,089 |
| Loss (gain) on the disposition of capital assets1,528(20)Charge for deferred loan costs and debt discount-16,022Asset impairment charge-12,602Gain on involuntary conversionOther, net1,741339Changes in assets and liabilities, net of effects from acquisitions:Decrease in accounts receivable5,378796(Increase) decrease in inventory(3,240)5,346Increase in other current assets1862,503Decrease in accounts payable(4,893)(2,273)(Decrease) increase in accrued liabilities(8,497)1,246Increase (decrease) in income taxes4,670(365)(Decrease) increase in deferred pension and postretirement benefits(271)588Increase in other long-term liabilities1,382956Other, net(2437)(93)Cash provided by operating activities78,55486,418Investing activities:(34,564)(37,243)Proceeds from disposition of capital assets1,9371,044Cash used for investing activities(41,124)(282,103)Financing activities:(11,435)Repayments of credit facility borrowings(98,875)(422,875)Debt issuance cots(11,435)Repayments of other long-term debt(2,722)(2,185)Common stock7,9533,400Repayments of other long-term debt(2,722)(2,185)Common stock <td< td=""><td>Deferred income tax</td><td></td><td>(112)</td><td></td><td>(8,469)</td></td<> | Deferred income tax | | (112) | | (8,469) |
| Charge for deferred loan costs and debt discount - 16,022 Asset impairment charge - 12,602 Gain on involuntary conversion - - Other, net 1,741 339 Changes in assets and liabilities, net of effects from acquisitions: - - Decrease in accounts receivable 5,378 796 (Increase) decrease in inventory (3,240) 5,346 Increase in other current assets 186 2,503 Decrease in accounts payable (4,893) (2,273) (Decrease) increase in accruel liabilities (8,497) 1,246 Increase (decrease) in income taxes 4,670 (365) (Decrease) increase in deferred pension and postretirement benefits (271) 588 Increase in other long-term liabilities 1,382 956 Other, net (437) (245,904) Cash provided by operating activities (34,564) (37,243) Proceeds from disposition of capital assets 1,937 1,044 Cash used for investing activities (41,124) (282,003) Financing | Excess tax benefit from share-based compensation | | (248) | | (136) |
| Asset impairment charge - 12,602 Gain on involuntary conversion - - Other, net 1,741 339 Changes in assets and liabilities, net of effects from acquisitions: - - Decrease in accounts receivable 5,378 796 (Increase) decrease in inventory (3,240) 5,346 Increase in other current assets 186 2,503 Decrease in accounts payable (4,893) (2,273) (Decrease) increase in accrued liabilities (8,497) 1,246 Increase (decrease) in income taxes 4,670 (365) (Decrease) increase in deferred pension and postretirement benefits (271) 588 Increase in other long-term liabilities 1,382 956 Other, net (437) (93) Cash provided by operating activities 78,554 86,418 Investing activities: (41,124) (282,103) Proceeds from disposition of capital assets 1,937 1,044 Cash used for investing activities 53,500 634,800 Repayments of other long-term debt | Loss (gain) on the disposition of capital assets | | 1,528 | | (20) |
| Gain on involuntary conversionOther, net1,741339Changes in assets and liabilities, net of effects from acquisitions:-Decrease in accounts receivable5,378796(Increase) decrease in inventory(3,240)5,346Increase in other current assets1862,503Decrease in accounts payable(4,893)(2,273)(Decrease) increase in accured liabilities(8,497)1,246Increase (decrease) in income taxes4,670(365)(Decrease) increase in deferred pension and postretirement benefits(271)588Increase in other long-term liabilities1,382956Other, net(437)(93)Cash provided by operating activities78,55486,418Investing activities:(8,497)(245,904)Capital expenditures(34,564)(37,243)Proceeds from disposition of capital assets1,9371,044Cash used for investing activities53,500634,800Repayments of credit facility borrowings(98,875)(422,875)Debt issuance costs-(11,435)Repayments of other long-term debt(2,722)(2,185)Common stock7,9533,400Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in acculated asch equivalents(80,71)2,401 <td>Charge for deferred loan costs and debt discount</td> <td></td> <td>-</td> <td></td> <td>16,022</td> | Charge for deferred loan costs and debt discount | | - | | 16,022 |
| Other, net 1,741 339 Changes in assets and liabilities, net of effects from acquisitions: 5,378 796 Decrease in accounts receivable 5,378 796 (Increase) decrease in inventory (3,240) 5,346 Increase in accounts payable (4,893) (2,273) (Decrease) increase in accured liabilities (8,497) 1,246 Increase (decrease) in income taxes (4,670) (365) (Decrease) increase in deferred pension and postretirement benefits (271) 588 Increase (nother long-term liabilities 1,382 956 Other, net (437) (93) Cash provided by operating activities 78,554 86,418 Investing activities: 78,554 86,418 Investing activities (34,564) (37,243) Proceeds from disposition of capital assets 1,937 1,044 Cash used for investing activities (41,124) (282,103) Financing activities: (41,124) (282,103) Borrowings under credit facilities 53,500 634,800 Repayments of c | Asset impairment charge | | - | | 12,602 |
| Changes in assets and liabilities, net of effects from acquisitions:Decrease in accounts receivable $5,378$ 796(Increase) decrease in inventory $(3,240)$ $5,346$ Increase in other current assets 186 $2,503$ Decrease in accounts payable $(4,893)$ $(2,273)$ (Decrease) increase in accrued liabilities $(8,497)$ $1,246$ Increase (decrease) in income taxes $4,670$ (365) (Decrease) increase in deferred pension and postretirement benefits (271) 588 Increase in other long-term liabilities $1,382$ 956 Other, net (437) (93) Cash provided by operating activities $78,554$ $86,418$ Investing activities: $(34,564)$ $(37,243)$ Proceeds from disposition of capital assets $1,937$ $1,044$ Cash used for investing activities $(4,1124)$ $(282,103)$ Financing activities: $(2,722)$ $(2,185)$ Debt issuance costs- $(11,435)$ Repayments of credit facilities $53,500$ $634,800$ Repayments of other long-term debt $(2,722)$ $(2,185)$ Common stock $7,953$ $3,400$ Excess tax benefit from share-based compensation 248 136 Cash uce for) provided by financing activities $(8,071)$ $2,401$ Cash and cash equivalents (8071) $2,401$ Cash and cash equivalents $(8,071)$ $2,401$ | Gain on involuntary conversion | | - | | - |
| Decrease in accounts receivable $5,378$ 796(Increase) decrease in inventory $(3,240)$ $5,346$ Increase in other current assets 186 $2,503$ Decrease in accounts payable $(4,893)$ $(2,273)$ (Decrease) increase in accrued liabilities $(8,497)$ $1,246$ Increase (decrease) in income taxes $4,670$ (365) (Decrease) increase in deferred pension and postretirement benefits (271) 588 Increase in other long-term liabilities $1,382$ 956 Other, net (437) (93) Cash provided by operating activities $78,554$ $86,418$ Investing activities: $78,554$ $86,418$ Investing activities: $1,937$ $1,044$ Capital expenditures $(34,564)$ $(37,243)$ Proceeds from disposition of capital assets $1,937$ $1,044$ Cash used for investing activities $1,937$ $1,044$ Employing under credit facilities $53,500$ $634,800$ Repayments of credit facilities $53,500$ $634,800$ Repayments of other long-term debt $(2,722)$ $(2,185)$ Common stock dividends paid $(5,516)$ $(5,470)$ Issuance of common stock $7,953$ $3,400$ Excess tax benefit from share-based compensation 248 136 Cash (used for) provided by financing activities $(45,412)$ $196,371$ Effect of exchange rate changes on cash and cash equivalents (89) $1,715$ (Decrease) increase in cash and cash equivalents $(89$ | Other, net | | 1,741 | | 339 |
| (Increase) decrease in inventory $(3,240)$ $5,346$ Increase in other current assets 186 $2,503$ Decrease in accounts payable $(4,893)$ $(2,273)$ (Decrease) increase in accrued liabilities $(8,497)$ $1,246$ Increase (decrease) in income taxes $4,670$ (365) (Decrease) increase in deferred pension and postretirement benefits (271) 588 Increase in other long-term liabilities $1,382$ 956 Other, net (437) (93) Cash provided by operating activities $78,554$ $86,418$ Investing activities: $(34,564)$ $(37,243)$ Proceeds from disposition of capital assets $1,937$ $1,044$ Cash used for investing activities $53,500$ $634,800$ Repayments of credit facilities $53,500$ $634,800$ Repayments of credit facilities $(2,722)$ $(2,185)$ Debt issuance costs- $(11,435)$ Repayments of credit facility borrowings $(98,875)$ $(422,875)$ Debt issuance costs- $(11,435)$ Repayments of ther long-term debt $(2,722)$ $(2,185)$ Common stock $7,953$ $3,400$ Excess tax benefit from share-based compensation 248 136 Cash (used for) provided by financing activities $(45,412)$ $196,371$ Effect of exchange rate changes on cash and cash equivalents (89) $1,715$ (Decrease) increase in cash and cash equivalents $(80,71)$ $2,401$ Cash and cash equivalents $(80,71)$ < | Changes in assets and liabilities, net of effects from acquisitions: | | | | |
| Increase in other current assets1862,503Decrease in accounts payable $(4,893)$ $(2,273)$ (Decrease) increase in accrued liabilities $(8,497)$ $1,246$ Increase (decrease) in income taxes $4,670$ (365) (Decrease) increase in deferred pension and postretirement benefits (271) 588 Increase in other long-term liabilities $1,382$ 956 Other, net (437) (93) Cash provided by operating activities $78,554$ $86,418$ Investing activities: $78,554$ $86,418$ Acquisitions, net of cash acquired $(8,497)$ $(245,904)$ Capital expenditures $(34,564)$ $(37,243)$ Proceeds from disposition of capital assets $1,937$ $1,044$ Cash used for investing activities $(41,124)$ $(282,103)$ Financing activities: $09,875$ $(422,875)$ Debt issuance costs- $(11,435)$ Repayments of other long-term debt $(2,722)$ $(2,185)$ Common stock dividends paid $(5,516)$ $(5,470)$ Issuance of common stock $7,953$ $3,400$ Excess tax benefit from share-based compensation 248 136 Cash (used for) provided by financing activities $(45,412)$ $196,371$ Effect of exchange rate changes on cash and cash equivalents (8071) $2,401$ Cash and cash equivalents at beginning of period $25,526$ $23,125$ | - | | 5,378 | | 796 |
| Increase in other current assets1862,503Decrease in accounts payable $(4,893)$ $(2,273)$ (Decrease) increase in accrued liabilities $(8,497)$ $1,246$ Increase (decrease) in income taxes $4,670$ (365) (Decrease) increase in deferred pension and postretirement benefits (271) 588 Increase in other long-term liabilities $1,382$ 956 Other, net (437) (93) Cash provided by operating activities $78,554$ $86,418$ Investing activities: $78,554$ $86,418$ Acquisitions, net of cash acquired $(8,497)$ $(245,904)$ Capital expenditures $(34,564)$ $(37,243)$ Proceeds from disposition of capital assets $1,937$ $1,044$ Cash used for investing activities $(41,124)$ $(282,103)$ Financing activities: $09,875$ $(422,875)$ Debt issuance costs- $(11,435)$ Repayments of other long-term debt $(2,722)$ $(2,185)$ Common stock dividends paid $(5,516)$ $(5,470)$ Issuance of common stock $7,953$ $3,400$ Excess tax benefit from share-based compensation 248 136 Cash (used for) provided by financing activities $(45,412)$ $196,371$ Effect of exchange rate changes on cash and cash equivalents (8071) $2,401$ Cash and cash equivalents at beginning of period $25,526$ $23,125$ | (Increase) decrease in inventory | | (3,240) | | 5,346 |
| Decrease in accounts payable $(4,893)$ $(2,273)$ (Decrease) increase in accrued liabilities $(8,497)$ $1,246$ Increase (decrease) in income taxes $4,670$ (365) (Decrease) increase in deferred pension and postretirement benefits (271) 588 Increase in other long-term liabilities $1,382$ 956 Other, net (437) (93) Cash provided by operating activities $78,554$ $86,418$ Investing activities: $78,554$ $86,418$ Investing activities: $(8,497)$ $(245,904)$ Capital expenditures $(34,564)$ $(37,243)$ Proceeds from disposition of capital assets $1,937$ $1,044$ Cash used for investing activities $(41,124)$ $(282,103)$ Financing activities: $(41,124)$ $(282,103)$ Debt issuance costs- $(11,435)$ Repayments of credit facilities $53,500$ $634,800$ Repayments of other long-term debt $(2,722)$ $(2,185)$ Common stock dividends paid $(5,516)$ $(5,470)$ Issuance of common stock $7,953$ $3,400$ Excess tax benefit from share-based compensation 248 136 Cash (used for) provided by financing activities $(45,412)$ $196,371$ Effect of exchange rate changes on cash and cash equivalents (89) $1,715$ (Decrease) increase in cash and cash equivalents $(8,071)$ $2,401$ Cash and cash equivalents at beginning of period $25,526$ $23,125$ | | | | | |
| (Decrease) increase in accrued liabilities $(8,497)$ $1,246$ Increase (decrease) in income taxes $4,670$ (365) (Decrease) increase in deferred pension and postretirement benefits (271) 588 Increase in other long-term liabilities $1,382$ 956 Other, net (437) (93) Cash provided by operating activities $78,554$ $86,418$ Investing activities: $(8,497)$ $(245,904)$ Capital expenditures $(34,564)$ $(37,243)$ Proceeds from disposition of capital assets $1,937$ $1,044$ Cash used for investing activities $(41,124)$ $(282,103)$ Financing activities: $(41,124)$ $(282,103)$ Borrowings under credit facilities $53,500$ $634,800$ Repayments of other long-term debt $(2,722)$ $(2,185)$ Common stock dividends paid $(5,516)$ $(5,470)$ Issuance of common stock $7,953$ $3,400$ Excess tax benefit from share-based compensation 248 136 Cash (used for) provided by financing activities $(45,412)$ $196,371$ Effect of exchange rate changes on cash and cash equivalents (80) $1,715$ (Decrease) increase in cash and cash equivalents (80) $1,715$ | Decrease in accounts payable | | (4,893) | | |
| Increase (decrease) in income taxes4,670(365)(Decrease) increase in deferred pension and postretirement benefits(271)588Increase in other long-term liabilities1,382956Other, net(437)(93)Cash provided by operating activities78,55486,418Investing activities:78,55486,418Acquisitions, net of cash acquired(8,497)(245,904)Capital expenditures(34,564)(37,243)Proceeds from disposition of capital assets1,9371,044Cash used for investing activities(41,124)(282,103)Financing activities:53,500634,800Repayments of credit facilities53,500634,800Repayments of other long-term debt(2,722)(2,185)Common stock dividends paid(5,516)(5,470)Issuance of common stock7,9533,400Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(80,71)2,401Cash and cash equivalents at beginning of period22,52623,125 | | | | | |
| (Decrease) increase in deferred pension and postretirement benefits (271) 588Increase in other long-term liabilities $1,382$ 956Other, net (437) (93) Cash provided by operating activities $78,554$ $86,418$ Investing activities: $78,554$ $86,418$ Investing activities: $(8,497)$ $(245,904)$ Capital expenditures $(34,564)$ $(37,243)$ Proceeds from disposition of capital assets $1,937$ $1,044$ Cash used for investing activities $(41,124)$ $(282,103)$ Financing activities: $(41,124)$ $(282,103)$ Borrowings under credit facilities $53,500$ $634,800$ Repayments of credit facility borrowings $(98,875)$ $(422,875)$ Debt issuance costs- $(11,435)$ Repayments of other long-term debt $(2,722)$ $(2,185)$ Common stock dividends paid $(5,516)$ $(5,470)$ Issuance of common stock $7,953$ $3,400$ Excess tax benefit from share-based compensation 248 136 Cash (used for) provided by financing activities $(45,412)$ $196,371$ Effect of exchange rate changes on cash and cash equivalents (89) $1,715$ (Decrease) increase in cash and cash equivalents $(8,071)$ $2,401$ Cash and cash equivalents at beginning of period $25,526$ $23,125$ | | | | | |
| Increase in other long-term liabilities1,382956Other, net(437)(93)Cash provided by operating activities78,55486,418Investing activities:78,55486,418Investing activities:(8,497)(245,904)Capital expenditures(34,564)(37,243)Proceeds from disposition of capital assets1,9371,044Cash used for investing activities(41,124)(282,103)Financing activities:(41,124)(282,103)Borrowings under credit facilities53,500634,800Repayments of credit facility borrowings(98,875)(422,875)Debt issuance costs-(11,435)Repayments of other long-term debt(2,722)(2,185)Common stock dividends paid(5,516)(5,470)Issuance of common stock7,9533,400Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(80)1,715(Decrease) increase in cash and cash equivalents(8,071)2,401Cash and cash equivalents at beginning of period25,52623,125 | | | • | | |
| Other, net(437)(93)Cash provided by operating activities78,55486,418Investing activities:78,55486,418Investing activities:(8,497)(245,904)Capital expenditures(34,564)(37,243)Proceeds from disposition of capital assets1,9371,044Cash used for investing activities(41,124)(282,103)Financing activities:(41,124)(282,103)Borrowings under credit facilities53,500634,800Repayments of credit facility borrowings(98,875)(422,875)Debt issuance costs-(11,435)Repayments of other long-term debt(2,722)(2,185)Common stock dividends paid(5,516)(5,470)Issuance of common stock7,9533,400Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(80,071)2,401Cash and cash equivalents at beginning of period25,52623,125 | | | | | |
| Cash provided by operating activities78,55486,418Investing activities:Acquisitions, net of cash acquired(8,497)(245,904)Capital expenditures(34,564)(37,243)Proceeds from disposition of capital assets1,9371,044Cash used for investing activities(41,124)(282,103)Financing activities:(41,124)(282,103)Borrowings under credit facilities53,500634,800Repayments of credit facility borrowings(98,875)(422,875)Debt issuance costs-(11,435)Repayments of other long-term debt(2,722)(2,185)Common stock dividends paid(5,516)(5,470)Issuance of common stock7,9533,400Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(8071)2,401Cash and cash equivalents at beginning of period225,52623,125 | - | | | | |
| Investing activities:Acquisitions, net of cash acquired(8,497)(245,904)Capital expenditures(34,564)(37,243)Proceeds from disposition of capital assets1,9371,044Cash used for investing activities(41,124)(282,103)Financing activities:(41,124)(282,103)Borrowings under credit facilities53,500634,800Repayments of credit facility borrowings(98,875)(422,875)Debt issuance costs-(11,435)Repayments of other long-term debt(2,722)(2,185)Common stock dividends paid(5,516)(5,470)Issuance of common stock7,9533,400Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(8071)2,401Cash and cash equivalents at beginning of period25,52623,125 | • | | | | |
| Acquisitions, net of cash acquired(8,497)(245,904)Capital expenditures(34,564)(37,243)Proceeds from disposition of capital assets1,9371,044Cash used for investing activities(41,124)(282,103)Financing activities:Borrowings under credit facilities53,500634,800Repayments of credit facility borrowings(98,875)(422,875)Debt issuance costs-(11,435)Repayments of other long-term debt(2,722)(2,185)Common stock dividends paid(5,516)(5,470)Issuance of common stock7,9533,400Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(8,071)2,401Cash and cash equivalents at beginning of period225,52623,125 | | | | | · |
| Capital expenditures(34,564)(37,243)Proceeds from disposition of capital assets1,9371,044Cash used for investing activities(41,124)(282,103)Financing activities:(41,124)(282,103)Borrowings under credit facilities53,500634,800Repayments of credit facility borrowings(98,875)(422,875)Debt issuance costs-(11,435)Repayments of other long-term debt(2,722)(2,185)Common stock dividends paid(5,516)(5,470)Issuance of common stock7,9533,400Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(8071)2,401Cash and cash equivalents at beginning of period225,52623,125 | - | | (8,497) | | (245,904) |
| Proceeds from disposition of capital assets1,9371,044Cash used for investing activities(41,124)(282,103)Financing activities:53,500634,800Repayments of credit facilities53,500634,800Repayments of credit facility borrowings(98,875)(422,875)Debt issuance costs-(11,435)Repayments of other long-term debt(2,722)(2,185)Common stock dividends paid(5,516)(5,470)Issuance of common stock7,9533,400Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(8,071)2,401Cash and cash equivalents at beginning of period25,52623,125 | | | | | |
| Cash used for investing activities(41,124)(282,103)Financing activities:(41,124)(282,103)Borrowings under credit facilities53,500634,800Repayments of credit facility borrowings(98,875)(422,875)Debt issuance costs-(11,435)Repayments of other long-term debt(2,722)(2,185)Common stock dividends paid(5,516)(5,470)Issuance of common stock7,9533,400Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(8,071)2,401Cash and cash equivalents at beginning of period25,52623,125 | | | | | |
| Financing activities:Borrowings under credit facilities53,500634,800Repayments of credit facility borrowings(98,875)(422,875)Debt issuance costs-(11,435)Repayments of other long-term debt(2,722)(2,185)Common stock dividends paid(5,516)(5,470)Issuance of common stock7,9533,400Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(8,071)2,401Cash and cash equivalents at beginning of period25,52623,125 | | | | | |
| Borrowings under credit facilities53,500634,800Repayments of credit facility borrowings(98,875)(422,875)Debt issuance costs-(11,435)Repayments of other long-term debt(2,722)(2,185)Common stock dividends paid(5,516)(5,470)Issuance of common stock7,9533,400Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(8,071)2,401Cash and cash equivalents at beginning of period25,52623,125 | - | | | | |
| Repayments of credit facility borrowings(98,875)(422,875)Debt issuance costs-(11,435)Repayments of other long-term debt(2,722)(2,185)Common stock dividends paid(5,516)(5,470)Issuance of common stock7,9533,400Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(8,071)2,401Cash and cash equivalents at beginning of period25,52623,125 | - | | 53,500 | | 634,800 |
| Debt issuance costs-(11,435)Repayments of other long-term debt(2,722)(2,185)Common stock dividends paid(5,516)(5,470)Issuance of common stock7,9533,400Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(8,071)2,401Cash and cash equivalents at beginning of period25,52623,125 | - | | (98,875) | | (422,875) |
| Repayments of other long-term debt(2,722)(2,185)Common stock dividends paid(5,516)(5,470)Issuance of common stock7,9533,400Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(8,071)2,401Cash and cash equivalents at beginning of period25,52623,125 | | | - | | |
| Common stock dividends paid(5,516)(5,470)Issuance of common stock7,9533,400Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(8,071)2,401Cash and cash equivalents at beginning of period25,52623,125 | | | (2,722) | | |
| Issuance of common stock7,9533,400Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(8,071)2,401Cash and cash equivalents at beginning of period25,52623,125 | | | | | |
| Excess tax benefit from share-based compensation248136Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(8,071)2,401Cash and cash equivalents at beginning of period25,52623,125 | • | | | | |
| Cash (used for) provided by financing activities(45,412)196,371Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(8,071)2,401Cash and cash equivalents at beginning of period25,52623,125 | | | | | |
| Effect of exchange rate changes on cash and cash equivalents(89)1,715(Decrease) increase in cash and cash equivalents(8,071)2,401Cash and cash equivalents at beginning of period25,52623,125 | · | | | | |
| (Decrease) increase in cash and cash equivalents(8,071)2,401Cash and cash equivalents at beginning of period25,52623,125 | | | | | |
| Cash and cash equivalents at beginning of period 25,526 23,125 | | | | | |
| | | | | | |
| | Cash and cash equivalents at end of period | \$ | 17,455 | \$ | 25,526 |

QUANEX BUILDING PRODUCTS CORPORATION NON-GAAP FINANCIAL MEASURE DISCLOSURE

(In thousands, except per share data) (Unaudited)

| | · · | Three Mon | | | | | Three Mon | | | 1 | 1 | welve Mor | | | 1 | | Twelve Mo | | | 1 |
|---|----------|----------------------|----------|-----------|-----|------|----------------------|-------|-----------|-----|------|------------------------|--------|----------|-----|----------|----------------------|--------|-----------|-------|
| Reconciliation of Adjusted Net Income and Adjusted EPS | | October | | | | | October | | | | | October 3 | | | | | October | | | |
| | | Net | | iluted | | | Net | | Diluted | | | Net | | iluted | | | Net | D | iluted | |
| | lı | ncome | | EPS | | | ncome | | EPS | _ | | ncome | | EPS | _ | | ncome | | EPS | _ |
| Net income (loss) as reported | \$ | 10,732 | \$ | 0.31 | | \$ | 5,431 | \$ | 0.16 | | \$ | 18,683 | \$ | 0.54 | | \$ | (1,859) | \$ | (0.05) | |
| Reconciling items from below | | 2,337 | | 0.06 | | | 10,214 | _ | 0.29 | - | | 8,303 | | 0.23 | - | | 29,551 | | 0.87 | |
| Adjusted Net income and Adjusted EPS | \$ | 13,069 | \$ | 0.37 | | \$ | 15,645 | \$ | 0.45 | | \$ | 26,986 | \$ | 0.77 | | \$ | 27,692 | \$ | 0.82 | - |
| Reconciliation of Adjusted EBITDA | | Three Mon October | | | | | Three Mon October | | | | ٦ | welve Mor October 3 | | | | | Twelve Mo October | | |] |
| | Reco | nciliation | | | | Reco | onciliation | | | | Reco | nciliation | | | | Rec | onciliation | | | |
| Net income (loss) as reported | \$ | 10,732 | | | | \$ | 5,431 | | | | \$ | 18,683 | | | | \$ | (1,859) | | | |
| Income tax (expense) benefit | | 3,188 | | | | | (1,043) | | | | | 6,819 | | | | | (3,765) | | | |
| Other, net | | (158) | | | | | 1,443 | | | | | (730) | | | | | 5,479 | | | |
| Interest expense | | 2,469 | | | | | 2,174 | | | | | 9,595 | | | | | 36,498 | | | |
| Depreciation and amortization | | 13,794 | | | | | 13,387 | | | | | 57,495 | | | | | 53,146 | | | |
| EBITDA | | 30,025 | | | | - | 21,392 | | | | - | 91,862 | | | | | 89,499 | | | |
| Reconciling items from below | | 3,263 | | | | | 13,164 | | | | | 7,156 | | | | | 20,790 | | | |
| Adjusted EBITDA | \$ | 33,288 | | | | \$ | 34,556 | | | | \$ | 99,018 | | | | \$ | 110,289 | | | |
| | <u> </u> | Three Mon | ths E | nded | | | Three Mon | ths E | nded | 1 | 1 | welve Mor | nths E | nded | 1 | — | Twelve Mo | nths E | inded | 1 |
| Reconciling Items | | October | 31, 20 | 17 | | | October | 31, 2 | 016 | | | October 3 | 31, 20 | 17 | | | October | 31, 20 | 016 | |
| | I | ncome | Rec | conciling | | I | ncome | Re | conciling | - | I | ncome | Rec | onciling | | I | ncome | Rec | conciling | - |
| | Sta | tement | 1 | ltems | | Sta | atement | | Items | | Sta | tement | I | tems | | Sta | atement | 1 | ltems | |
| Net sales | \$ | 232,959 | \$ | - | | \$ | 249,171 | \$ | - | - | \$ | 866,555 | \$ | - | - | \$ | 928,184 | \$ | - | - |
| Cost of sales | | 178,325 | | - | | | 188,168 | | (32) | (1) | | 672,162 | | (104) | (1) | | 710,644 | | (2,671) |) (1) |
| Selling, general and administrative | | 23,142 | | (1,796) | (2) | | 26,480 | | (1) | (2) | | 97,981 | | (2,502) | (2) | | 114,910 | | (4,988) |) (2) |
| Restructuring charges | | 1,467 | | (1,467) | (3) | | 529 | | (529) | (3) | | 4,550 | | (4,550) | (3) | | 529 | | (529) |) (3) |
| EBITDA | | 30,025 | | 3,263 | | _ | 33,994 | | 562 | | | 91,862 | | 7,156 | | | 102,101 | | 8,188 | |
| Asset impairment charges | | - | | | | | 12,602 | | (12,602) | (4) | | - | | | | | 12,602 | | (12,602) |) (4) |
| Depreciation and amortization | | 13,794 | | (731) | (5) | | 13,387 | | (1,295) | (5) | | 57,495 | | (6,233) | (4) | | 53,146 | | (1,295 | |
| Operating income (loss) | | 16,231 | | 3,994 | | | 8,005 | | 14,459 | | | 34,367 | | 13,389 | | | 36,353 | | 22,085 | |
| Interest expense | | (2,469) | | - | | | (2,174) | | - | | | (9,595) | | - | | | (36,498) | | 16,677 | |
| Other, net | | 158 | | (111) | (6) | | (1,443) | | 1,501 | (6) | | 730 | | (625) | (6) | | (5,479) | | 5,380 | |
| Income (loss) before income taxes | | 13,920 | | 3,883 | | | 4,388 | | 15,960 | | | 25,502 | | 12,764 | | | (5,624) | | 44,142 | |
| Income tax (expense) benefit | | (3,188) | | (1,546) | (7) | | 1,043 | | (5,746) | (7) | | (6,819) | | (4,461) | (7) | | 3,765 | | (14,591) | |
| Net income (loss) | \$ | 10,732 | \$ | 2,337 | . / | \$ | 5,431 | \$ | 10,214 | . / | \$ | 18,683 | \$ | 8,303 | . / | \$ | (1,859) | \$ | 29,551 | / |
| Diluted earnings (loss) per share | \$ | 0.31 | , | , | | \$ | 0.16 | • | .,==. | | \$ | 0.54 | | ., | | \$ | (0.05) | | ., | |
| Relates solely to purchase price accounting inventory step-up in Acquisition related transaction costs and the loss on the sale of | npact f | rom HL Plas | tics acc | uisition. | | | | | | | , | | | | | Ŧ | () | | | |

Relates solely to purchase price accounting inventory step-up inpact from HL Plastics at (2) Acquisiton related transaction costs, and the loss on the sale of plant in 4Q17.
 Restructuring charges relate to the closure of several manufacturing plant facilities.
 Impairment of good/will at United States vinvi business in 2016.
 Accelerated depreciation and amortization for restructured PP&E and intangible assets.
 Foreign currency transaction (agins) losse.
 Tipmact on a with and without basis.

QUANEX BUILDING PRODUCTS CORPORATION SEGMENT RECONCILIATION

(In thousands)

(Unaudited)

The following tables reconcile the Company's segment presentation to account for the transfer of operating facilities from the North American Engineered Components segment to the Cabinet Components segment, as previously reported in our earnings release for the three-months and twelve-months ended October 31, 2016, to the current presentation:

| current presentation: | | Engineered mponents | | ngineered nponents | | Cabinet | | Unallocated Corp & Other | | Total |
|--------------------------------------|----------|------------------------|----|-----------------------|----|----------|----|-----------------------------|----|---------|
| Three months ended October 31, 2016 | | nponents | | iponents | | iponents | | | | |
| As previously reported | | | | | | | | | | |
| Net sales | \$ | 154,000 | \$ | 39,953 | \$ | 56,485 | \$ | (1,267) | \$ | 249,171 |
| Cost of sales | | 111,491 | | 27,754 | | 49,844 | | (921) | | 188,168 |
| Selling, general and administrative | | 16,548 | | 5,817 | | 2,554 | | 1,561 | | 26,480 |
| Restructuring costs | | 387 | | - | | 142 | | - | | 529 |
| Depreciation and amortization | | 8,874 | | 2,148 | | 2,239 | | 126 | | 13,387 |
| Asset impairment charges | | 12,602 | | - | | - | | - | | 12,602 |
| Operating income (loss) | \$ | 4,098 | \$ | 4,234 | \$ | 1,706 | \$ | (2,033) | \$ | 8,005 |
| Reclassification | | | | | | | | | | |
| Net sales | \$ | (6,007) | \$ | - | \$ | 6,598 | \$ | (591) | \$ | - |
| Cost of sales | 4 | (4,329) | + | - | Ŧ | 4,920 | Ŧ | (591) | Ŧ | - |
| Selling, general and administrative | | (237) | | _ | | 194 | | 43 | | _ |
| Restructuring costs | | (257) | | _ | | - | | - | | _ |
| Depreciation and amortization | | (131) | | _ | | 131 | | _ | | _ |
| Asset impairment charges | | (151) | | _ | | 151 | | - | | |
| Operating income (loss) | \$ | (1,310) | \$ | | \$ | 1,353 | \$ | - (43) | \$ | - |
| | | <u> </u> | | | | <u> </u> | | · · | | |
| Current presentation | | | | | | | | | | |
| Net sales | \$ | 147,993 | \$ | 39,953 | \$ | 63,083 | \$ | (1,858) | \$ | 249,171 |
| Cost of sales | | 107,162 | | 27,754 | | 54,764 | | (1,512) | | 188,168 |
| Selling, general and administrative | | 16,311 | | 5,817 | | 2,748 | | 1,604 | | 26,480 |
| Restructuring costs | | 387 | | - | | 142 | | - | | 529 |
| Depreciation and amortization | | 8,743 | | 2,148 | | 2,370 | | 126 | | 13,387 |
| Asset impairment charges | | 12,602 | | - | | - | | - | | 12,602 |
| Operating income (loss) | \$ | 2,788 | \$ | 4,234 | \$ | 3,059 | \$ | (2,076) | \$ | 8,005 |
| Twelve months ended October 31, 2016 | | | | | | | | | | |
| As previously reported | | | | | | | | | | |
| Net sales | \$ | 560,029 | \$ | 150,203 | \$ | 223,391 | \$ | (5,439) | \$ | 928,184 |
| Cost of sales | 4 | 415,925 | + | 104,452 | Ŧ | 193,560 | Ŧ | (3,293) | Ŧ | 710,644 |
| Selling, general and administrative | | 62,934 | | 23,187 | | 14,920 | | 13,869 | | 114,910 |
| Restructuring costs | | 387 | | - | | 142 | | - | | 529 |
| Depreciation and amortization | | 30,298 | | 9,339 | | 12,948 | | 561 | | 53,146 |
| Asset impairment charges | | 12,602 | | 5,555 | | 12,540 | | 501 | | 12,602 |
| Operating income (loss) | \$ | 37,883 | \$ | 13,225 | \$ | 1,821 | \$ | (16,576) | \$ | 36,353 |
| | | · | | <u> </u> | | <u> </u> | | <u> </u> | | |
| Reclassification | | (21,700) | | | | 24 720 | | (2.0.40) | | |
| Net sales | \$ | (21,780) | \$ | - | \$ | 24,728 | \$ | (2,948) | \$ | - |
| Cost of sales | | (16,770) | | - | | 19,718 | | (2,948) | | - |
| Selling, general and administrative | | (851) | | - | | 851 | | - | | - |
| Restructuring costs | | - | | - | | - | | - | | - |
| Depreciation and amortization | | (505) | | - | | 505 | | - | | - |
| Asset impairment charges | | - | | - | | - | | - | | - |
| Operating income (loss) | \$ | (3,654) | \$ | - | \$ | 3,654 | \$ | - | \$ | - |
| Current presentation | | | | | | | | | | |
| Net sales | \$ | 538,249 | \$ | 150,203 | \$ | 248,119 | \$ | (8,387) | \$ | 928,184 |
| Cost of sales | | 399,155 | | 104,452 | | 213,278 | • | (6,241) | | 710,644 |
| Selling, general and administrative | | 62,083 | | 23,187 | | 15,771 | | 13,869 | | 114,910 |
| Restructuring costs | | 387 | | | | 142 | | - | | 529 |
| Depreciation and amortization | | 29,793 | | 9,339 | | 13,453 | | 561 | | 53,146 |
| Asset impairment charges | | 12,602 | | - | | | | - | | 12,602 |
| Operating income (loss) | \$ | 34,229 | \$ | - 13,225 | \$ | 5,475 | \$ | (16,576) | \$ | 36,353 |
| operating income (ioss) | <u>₽</u> | J7,229 | P | 13,223 | ą | J,473 | ą | (10,570) | P | 20,222 |

QUANEX BUILDING PRODUCTS CORPORATION SELECTED SEGMENT DATA

(In thousands)

(Unaudited)

This table provides operating income (loss), EBITDA, and Adjusted EBITDA by reportable segment. Non-operating expense and income tax expense are not allocated to the reportable segments.

| segments. | NA | EU E | ingineered | NA | Cabinet | | allocated | | Total | |
|--|----|----------|------------|----------|---------|----------|-----------|-----------|----------|---------|
| | Co | mponents | Cor | mponents | Cor | mponents | Cor | p & Other | | iotai |
| Three months ended October 31, 2017 | | | | | | | | | | |
| Net sales | \$ | 131,380 | \$ | 41,830 | \$ | 61,110 | \$ | (1,361) | \$ | 232,959 |
| Cost of sales | | 97,523 | | 29,572 | | 52,214 | | (984) | | 178,325 |
| Selling, general and administrative | | 14,076 | | 5,449 | | 3,887 | | (270) | | 23,142 |
| Restructuring charges | | 1,357 | | - | | 110 | | - | | 1,467 |
| Depreciation and amortization | | 7,932 | | 2,080 | | 3,650 | | 132 | | 13,794 |
| Operating income (loss) | | 10,492 | | 4,729 | | 1,249 | | (239) | | 16,231 |
| Depreciation and amortization | | 7,932 | | 2,080 | | 3,650 | | 132 | | 13,794 |
| EBITDA | | 18,424 | | 6,809 | | 4,899 | | (107) | | 30,025 |
| Transaction related costs | | - | | - | | - | | 169 | | 169 |
| Loss on sale of plant | | 1,627 | | - | | - | | - | | 1,627 |
| Restructuring charges | | 1,357 | | - | | 110 | | - | | 1,467 |
| Adjusted EBITDA | \$ | 21,408 | \$ | 6,809 | \$ | 5,009 | \$ | 62 | \$ | 33,288 |
| Adjusted EBITDA Margin % | | 16.3% | | 16.3% | | 8.2% | | | | 14.3% |
| Three months ended October 31, 2016 | | | | | | | | | | |
| Net sales | \$ | 147,993 | \$ | 39,953 | \$ | 63,083 | \$ | (1,858) | \$ | 249,171 |
| Cost of sales | | 107,162 | | 27,754 | | 54,764 | | (1,512) | | 188,168 |
| Selling, general and administrative | | 16,311 | | 5,817 | | 2,748 | | 1,604 | | 26,480 |
| Restructuring charges | | 387 | | - | | 142 | | - | | 529 |
| Depreciation and amortization | | 8,743 | | 2,148 | | 2,370 | | 126 | | 13,387 |
| Asset impairment charges | | 12,602 | | · - | | - | | - | | 12,602 |
| Operating income (loss) | | 2,788 | | 4,234 | | 3,059 | | (2,076) | | 8,005 |
| Depreciation and amortization | | 8,743 | | 2,148 | | 2,370 | | 126 | | 13,387 |
| EBITDA | | 11,531 | | 6,382 | | 5,429 | | (1,950) | | 21,392 |
| Transaction related costs | | | | - | | - | | 1 | | 1 |
| Restructuring charges | | 387 | | - | | 142 | | | | 529 |
| Asset impairment charges | | 12,602 | | - | | - | | _ | r. | 12,602 |
| PPA-Inventory Step-up | | - | | 32 | | - | | _ | | 32 |
| Adjusted EBITDA | \$ | 24,520 | \$ | 6,414 | \$ | 5,571 | \$ | (1,949) | \$ | 34,556 |
| Adjusted EBITDA Margin % | | 16.6% | ų | 16.1% | ų | 8.8% | Ψ | (1,515) | ų | 13.9% |
| Twelve months ended October 31, 2017 | | 10/070 | | 10/1/0 | | 0.070 | | | | 101010 |
| • | * | 474 070 | * | 147.963 | * | 240 000 | * | (E 004) | * | 866,555 |
| Net sales | \$ | 474,878 | \$ | 1 | \$ | 248,808 | \$ | (5,094) | \$ | |
| Cost of sales | | 357,806 | | 104,876 | | 213,257 | | (3,777) | | 672,162 |
| Selling, general and administrative | | 52,889 | | 20,581 | | 16,626 | | 7,885 | | 97,981 |
| Restructuring charges | | 3,564 | | - | | 986 | | - | | 4,550 |
| Depreciation and amortization | | 34,308 | | 8,833 | | 13,811 | | 543 | | 57,495 |
| Operating income (loss) | | 26,311 | | 13,673 | | 4,128 | | (9,745) | | 34,367 |
| Depreciation and amortization | | 34,308 | | 8,833 | | 13,811 | | 543 | | 57,495 |
| EBITDA | | 60,619 | | 22,506 | | 17,939 | | (9,202) | | 91,862 |
| Transaction related costs | | - | | - | | - | | 497 | | 497 |
| Mexico restructuring, loss on disposal of fixed assets | | - | | - | | 190 | | - | | 190 |
| One-time employee benefit adjustment | | - | | - | | 188 | | - | | 188 |
| PPA-Inventory Step-up | | - | | 104 | | - | | - | | 104 |
| Loss on sale of plant | | 1,627 | | - | | - | | - | | 1,627 |
| Restructuring charges | | 3,564 | | - | | 986 | | - | | 4,550 |
| Asset impairment charges | | - | | - | | - | | - | | - |
| Adjusted EBITDA | \$ | 65,810 | \$ | 22,610 | \$ | 19,303 | \$ | (8,705) | \$ | 99,018 |
| Adjusted EBITDA Margin % | | 13.9% | | 15.3% | | 7.8% | | | | 11.4% |
| Twelve months ended October 31, 2016 | | | | | | | | | | |
| Net sales | \$ | 538,249 | \$ | 150,203 | \$ | 248,119 | \$ | (8,387) | \$ | 928,184 |
| Cost of sales | | 399,155 | | 104,452 | | 213,278 | | (6,241) | | 710,644 |
| Selling, general and administrative | | 62,083 | | 23,187 | | 15,771 | | 13,869 | | 114,910 |
| Restructuring charges | | 387 | | - | | 142 | | - | | 529 |
| Depreciation and amortization | | 29,793 | | 9,339 | | 13,453 | | 561 | | 53,146 |
| Asset impairment charges | | 12,602 | | - | | - | | - | | 12,602 |
| Operating income (loss) | | 34,229 | | 13,225 | | 5,475 | | (16,576) | | 36,353 |
| Depreciation and amortization | | 29,793 | | 9,339 | | 13,453 | | 561 | | 53,146 |
| EBITDA | | 64,022 | | 22,564 | | 18,928 | | (16,015) | | 89,499 |
| Transaction related costs | | · - | | · - | | - | | 4,988 | | 4,988 |
| Restructuring charges | | 387 | | - | | 142 | | - | | 529 |
| Asset impairment charges | | 12,602 | | - | | - | | - | | 12,602 |
| PPA-Inventory Step-up | | - | | 384 | | 2,287 | | - | | 2,671 |
| Adjusted EBITDA | \$ | 77,011 | \$ | 22,948 | \$ | 21,357 | \$ | (11,027) | \$ | 110,289 |
| Adjusted EBITDA Margin % | | 14.3% | | 15.3% | | 8.6% | | | <u> </u> | 11.9% |
| | | 1.10.10 | | 10.0.0 | | 0.070 | | | | 11.570 |

QUANEX BUILDING PRODUCTS CORPORATION SALES ANALYSIS

(In thousands) (Unaudited)

| | | Three Months Ended | | | | | | ded |
|---|-------|--------------------|--------|---------------------------|--------------|-------------------|----------|----------------------------------|
| | Octob | <u>er 31, 2017</u> | Octobe | r 31, 2016 ⁽¹⁾ | <u>Octob</u> | ctober 31, 2017 (| | <u>r 31, 2016 ⁽¹⁾</u> |
| NA Engineered Components: | | | | | | | | |
| United States - fenestration ⁽²⁾ | \$ | 110,659 | \$ | 124,670 | \$ | 399,694 | \$ | 444,571 |
| International - fenestration | | 9,334 | | 9,530 | | 34,279 | | 38,439 |
| United States - non-fenestration | | 5,673 | | 8,677 | | 25,263 | | 36,986 |
| International - non-fenestration | | 5,714 | | 5,116 | | 15,642 | | 18,253 |
| | \$ | 131,380 | \$ | 147,993 | \$ | 474,878 | \$ | 538,249 |
| EU Engineered Components ⁽³⁾ : | | | | | | | | |
| United States - fenestration | \$ | - | \$ | 159 | \$ | 303 | \$ | 412 |
| International - fenestration | | 37,015 | | 35,283 | | 129,140 | | 134,631 |
| International - non-fenestration | | 4,815 | | 4,511 | | 18,520 | | 15,160 |
| | \$ | 41,830 | \$ | 39,953 | \$ | 147,963 | \$ | 150,203 |
| NA Cabinet Components: | | | | | | | | |
| United States - fenestration | \$ | 5,597 | \$ | 3,008 | \$ | 17,083 | \$ | 21,779 |
| United States - non-fenestration ⁽⁴⁾ | | 54,977 | | 59,431 | | 229,550 | | 223,664 |
| International - non-fenestration | | 536 | | 644 | | 2,175 | | 2,676 |
| | \$ | 61,110 | \$ | 63,083 | \$ | 248,808 | \$ | 248,119 |
| Unallocated Corporate & Other: | | | | | | | | |
| Eliminations | \$ | (1,361) | \$ | (1,858) | \$ | (5,094) | \$ | (8,387) |
| | \$ | (1,361) | \$ | (1,858) | \$ | (5,094) | \$ \$ | (8,387) |
| Net Sales | \$ | 232,959 | \$ | 249,171 | \$ | 866,555 | \$ | 928,184 |

Updated to reflect transfer of operating facilities from NA Engineered Components to NA Cabinet Components. See Reconciliation for additional details.
 Reflects the loss of revenue associated with eliminated products of \$14.5 million and \$67.9 million for the three-months and twelve-months ended October 31, 2017,

(3) Reflects a gain of \$1.0 million, and a loss \$10.7 million in revenue associated with foreign currency impacts for the three-months and twelve-months ended October 31, 2017, respectively.

(4) Reflects the loss of revenue associated with eliminated products of \$2.0 million and \$10.3 million for the three-months and twelve-months ended October 31, 2017, respectively.